London, October 6, 2026 / PRNewswire / -- Clarivate Plc (New York Stock Exchange ticker: CLVT) ("Clarivate" or "the Company") announced today that it has successfully completed the sale of its Life Sciences and Healthcare business units to Altaris, LLC ("Altaris"). This transaction advances Clarivate's transformation and simplifies its business portfolio. The transaction amount is $600 million, which was announced on July 6, 2026.
With the completion of this transaction, Clarivate has now become a more focused, subscription-oriented global provider, offering reliable proprietary data, authoritative content, AI-powered intelligent solutions, embedded workflow software, and technical support services. The company's leading two business divisions, Academia & Government, along with Intellectual Property, rely on the profound expertise of its Clarivate employees and shared infrastructure to support customers at critical moments such as innovation, research, learning, and the creation and protection of intellectual property, helping organizations move from information overload to more confident decision-making.
Clarivate CEO Matti Shem Tov stated: "This is an important milestone in Clarivate's transformation journey. The successful completion of this transaction further advances our value creation plan, helping us to focus on our business, simplify our portfolio, and strengthen our financial position. We are now a more focused company, centered around two market-leading business segments that feature attractive recurring revenues, deep customer relationships, and significant opportunities for innovation driven by AI."
"I would like to thank the members of our Life Sciences and Healthcare teams for their many contributions to Clarivate, and I wish them continued success as part of Altaris," Shem Tov continued. "We are also grateful for the trust and cooperation that our customers have provided throughout this process."
As previously mentioned, Clarivate intends to use the proceeds from the transaction to reduce debt and further strengthen its balance sheet, while also enhancing strategic and financial flexibility. This transaction also supports the company's efforts to improve revenue quality, expand profitability, and focus more on long-term value creation.
Clarivate Chief Financial Officer Michael Easton stated: "The completion of this transaction marks another important step in our strategic execution. Our streamlined business model and stronger balance sheet enable us to invest more effectively in innovation, support our customers, and drive sustainable growth and shareholder value."
The company will announce its financial results for the third quarter of fiscal year 2026 on Tuesday, November 3, 2026, and will update its full-year guidance for fiscal year 2026 to reflect the divestiture of the Life Sciences and Healthcare business units.
Focused Clarivate
After the divestiture, the business portfolio of Clarivate includes:
- Academia & GovernmentProvides reliable intelligence, workflow solutions, and services to help universities, research institutions, libraries, governments, and funders accelerate research, advance learning, and improve outcomes. Its portfolio includes leading research, education, and library solutions such as Web, of, Science, ProQuest, Alma, and Vega.
- Intellectual PropertyProvides leading patent, trademark, brand protection, and innovation intelligence solutions to help organizations create, protect, and commercialize intellectual property. Its portfolio includes IPOne, Derwent, CompuMark, IPfolio, and other cutting-edge intellectual property solutions.
Both of these services are built on proprietary content, workflow software, and the continuously expanding capabilities of AI, helping customers to make decisions more quickly and wisely.
Forward-looking Statements
This press release contains statements that express our views, expectations, beliefs, plans, objectives, assumptions, or predictions regarding future events or future results. Therefore, under the “safe harbor” provisions of the 1995 Private Securities Litigation Reform Act, they constitute or may be deemed to constitute “forward-looking statements.” These forward-looking statements include all matters that are not historical facts, such as our plans regarding the divestiture of Life Sciences & Healthcare businesses or other strategic transactions we may consider, the anticipated uses of proceeds from the divestiture, any expected cost savings or other benefits that may result from the divestiture, our financial guidance for the fiscal year 2026 and its key drivers and underlying assumptions, the impact or expected benefits of our value creation plan, growth strategies and future business prospects, global macroeconomic uncertainties and fluctuations, the impact of artificial intelligence on our business and strategy, and statements related to the timing of the aforementioned matters. Such forward-looking statements can typically be identified by words such as “believe,” “estimate,” “expect,” “anticipate,” “intend,” “predict,” “plan,” “may,” “will,” “should,” and their negative forms, as well as other similar expressions. These forward-looking statements are based on current market information available to us as well as management’s expectations, beliefs, and predictions regarding future events that may affect us. Forward-looking statements involve various risks and uncertainties (some of which are beyond our control) or other assumptions that could cause actual results or performance to differ significantly from those expressed or implied in these forward-looking statements. These risks and uncertainties include, but are not limited to, the factors described in our annual report Form 10-K under 1A. Risk Factors, as well as factors described in other documents we have submitted to the U.S. Securities and Exchange Commission (“SEC”).We cannot guarantee that future developments will meet our expectations. If one or more risks or uncertainties materialize, or if any assumptions prove to be incorrect, the actual results may differ significantly from those predicted in these forward-looking statements. Except as required by securities laws, we have no obligation to update or revise any forward-looking statements due to new information, future events, or other reasons. Please refer to the public documents we have submitted to SEC; these documents are also available on our website at www.clarivate.com.
About Clarivate
Clarivate is a leading global provider of transformation intelligence. We offer enhanced data, insights and analytics, workflow solutions, and expert services in the fields of Academia, Government, and Intellectual Property. For more information, please visit www.clarivate.com.
